Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: Sixteen type 2 diabetic patients and 12 control subjects received a meal, an oral glucose tolerance test (OGTT), and two hyperglycemic clamps, with or without GLP-1. The clamps were repeated in diabetic patients after 2 months of strict glycemic control. RESULTS: During the meal, glycemia, nitrotyrosine, and plasma 8-iso prostaglandin F2α (8-iso-PGF2a) remained unchanged in the control subjects, whereas they increased in diabetic patients. Flow-mediated vasodilation (FMD) decreased in diabetes, whereas GLP-1 increased in both groups. During the OGTT, an increase in glycemia, nitrotyrosine, and 8-iso-PGF2a and a decrease in FMD were observed at 1 h in the control subjects and at 1 and 2 h in the diabetic patients. In the same way, GLP-1 increased in both groups at the same levels of the meal. During the clamps, in both the control subjects and the diabetic patients, a significant increase in nitrotyrosine and 8-iso-PGF2a and a decrease in FMD were observed, effects that were significantly reduced by GLP-1. After improved glycemic control, hyperglycemia during the clamps was less effective in producing oxidative stress and endothelial dysfunction and the GLP-1 administration was most effective in reducing these effects. CONCLUSIONS: Our data suggest that during the meal GLP-1 can simultaneously exert an incretin effect on insulin secretion and a protective effect on endothelial function, reasonably controlling oxidative stress generation. The ability of GLP-1 in protecting endothelial function seems to depend on the level of glycemia, a phenomenon already described for insulin secretion.
|
Authors | Antonio Ceriello, Katherine Esposito, Roberto Testa, Anna Rita Bonfigli, Maurizio Marra, Dario Giugliano |
Journal | Diabetes care
(Diabetes Care)
Vol. 34
Issue 3
Pg. 697-702
(Mar 2011)
ISSN: 1935-5548 [Electronic] United States |
PMID | 21273492
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- 3-nitrotyrosine
- Tyrosine
- Glucagon-Like Peptide 1
|
Topics |
- Diabetes Mellitus
(drug therapy, metabolism)
- Endothelium, Vascular
(drug effects)
- Female
- Glucagon-Like Peptide 1
(therapeutic use)
- Glucose Tolerance Test
- Humans
- Male
- Middle Aged
- Tyrosine
(analogs & derivatives, metabolism)
- Vasodilation
(drug effects)
|